A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD1775 (MK1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
This is a phase 2 (the second phase in testing a new drug or drug combination, to see how
useful the drug or combination is) of chemotherapy drug, gemcitabine, when given alone or in
combination with investigational drug, AZD 1775 (also called MK-1775), in patients with
recurrent (the cancer has returned), platinum-resistant (the cancer does not respond to
platinum-based therapies) ovarian, peritoneal or fallopian tube cancers.
Gemcitabine is a chemotherapy drug commonly used to treat patients with recurrent,
platinumresistant ovarian, peritoneal or fallopian tube cancers. Gemcitabine works by
preventing tumour cells from multiplying by damaging their DNA, which in turn stops the tumour
from growing. However, a protein, called Wee1, may play a role in helping to repair damaged
tumour cells, so that the tumour continues to grow.
AZD 1775 (MK-1775) is a new drug which may block Wee1 protein activity. When given in
combination with gemcitabine, AZD 1775 (MK-1775) may help prevent the Wee1 protein from
repairing damaged tumour cells without causing harm to normal cells. This is believed to
increase the effectiveness of gemcitabine.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society